PURPOSE: Neutropenia and subsequent infections are life-threatening treatment-related toxicities of chemotherapy. Among patients with cancer, hospitalizations related to neutropenic complications result in substantial medical costs, morbidity, and mortality. Previous estimates for the cost of cancer-related neutropenia hospitalizations are based on older and limited data. This study provides nationally representative estimates of the cost of cancer-related neutropenia hospitalizations. METHODS: We examined data from the 2012 National Inpatient Sample and Kids' Inpatient Database. Hospitalizations for cancer-related neutropenia were defined as those with a primary or secondary diagnosis of cancer and a diagnosis of neutropenia or a fever of unknown origin. We examined characteristics of cancer-related neutropenia hospitalizations among children (age < 18 years) and adults (age ≥ 18 years). Adjusted predicted margins were used to estimate length of stay and cost per stay. RESULTS: There were 91,560 and 16,859 cancer-related neutropenia hospitalizations among adults and children, respectively. Total cost of cancer-related neutropenia hospitalizations was $2.3 billion for adults and $439 million for children. Cancer-related neutropenia hospitalizations accounted for 5.2% of all cancer-related hospitalizations and 8.3% of all cancer-related hospitalization costs. For adults, the mean length of stay for cancer-related neutropenia hospitalizations was 9.6 days, with a mean hospital cost of $24,770 per stay. For children, the mean length of stay for cancer-related neutropenia hospitalizations was 8.5 days, with a mean hospital cost of $26,000 per stay. CONCLUSION: We found the costs of cancer-related neutropenia hospitalizations to be substantially high. Efforts to prevent and minimize neutropenia-related complications among patients with cancer may decrease hospitalizations and associated costs.
PURPOSE:Neutropenia and subsequent infections are life-threatening treatment-related toxicities of chemotherapy. Among patients with cancer, hospitalizations related to neutropenic complications result in substantial medical costs, morbidity, and mortality. Previous estimates for the cost of cancer-related neutropenia hospitalizations are based on older and limited data. This study provides nationally representative estimates of the cost of cancer-related neutropenia hospitalizations. METHODS: We examined data from the 2012 National Inpatient Sample and Kids' Inpatient Database. Hospitalizations for cancer-related neutropenia were defined as those with a primary or secondary diagnosis of cancer and a diagnosis of neutropenia or a fever of unknown origin. We examined characteristics of cancer-related neutropenia hospitalizations among children (age < 18 years) and adults (age ≥ 18 years). Adjusted predicted margins were used to estimate length of stay and cost per stay. RESULTS: There were 91,560 and 16,859 cancer-related neutropenia hospitalizations among adults and children, respectively. Total cost of cancer-related neutropenia hospitalizations was $2.3 billion for adults and $439 million for children. Cancer-related neutropenia hospitalizations accounted for 5.2% of all cancer-related hospitalizations and 8.3% of all cancer-related hospitalization costs. For adults, the mean length of stay for cancer-related neutropenia hospitalizations was 9.6 days, with a mean hospital cost of $24,770 per stay. For children, the mean length of stay for cancer-related neutropenia hospitalizations was 8.5 days, with a mean hospital cost of $26,000 per stay. CONCLUSION: We found the costs of cancer-related neutropenia hospitalizations to be substantially high. Efforts to prevent and minimize neutropenia-related complications among patients with cancer may decrease hospitalizations and associated costs.
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: Alexandre Macedo de Oliveira; Kathryn L White; Dennis P Leschinsky; Brady D Beecham; Tara M Vogt; Ronald L Moolenaar; Joseph F Perz; Thomas J Safranek Journal: Ann Intern Med Date: 2005-06-07 Impact factor: 25.391
Authors: José Ignacio Mayordomo; Andrés López; Núria Viñolas; Javier Castellanos; Sonia Pernas; Juan Domingo Alonso; Adolfo Frau; Miquel Layola; José Antonio Gasquet; Jordi Sánchez Journal: Curr Med Res Opin Date: 2009-10 Impact factor: 2.580
Authors: Alberto Pablo-Trinidad; Ian Butterworth; María J Ledesma-Carbayo; Tom Vettenburg; Álvaro Sánchez-Ferro; Luis Soenksen; Nicholas J Durr; Arrate Muñoz-Barrutia; Carolina Cerrato; Karem Humala; Marta Fabra Urdiol; Candice Del Rio; Betsy Valles; Yi-Bin Chen; Ephraim P Hochberg; Carlos Castro-González; Aurélien Bourquard Journal: Am J Hematol Date: 2019-06-06 Impact factor: 10.047
Authors: Camille C Gunderson; Britt K Erickson; Ivy Wilkinson-Ryan; Sara K Vesely; Charles A Leath; Paola A Gehrig; Kathleen N Moore Journal: Am J Clin Oncol Date: 2019-02 Impact factor: 2.339
Authors: Nishant Verma; Iman Haji-Abolhassani; Suhas Ganesh; Jesus Vera-Aguilera; Jonas Paludo; Roxana Heitz; Svetomir N Markovic; Kimary Kulig; Atiyeh Ghoreyshi Journal: IEEE J Transl Eng Health Med Date: 2021-07-19 Impact factor: 3.316
Authors: Vikram Jairam; Victor Lee; Henry S Park; Charles R Thomas; Edward R Melnick; Cary P Gross; Carolyn J Presley; Kerin B Adelson; James B Yu Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: Mary Slavcev; Allison Spinelli; Elisabeth Absalon; Tara Masterson; Christoph Heuck; Annette Lam; Erwin De Cock Journal: Clinicoecon Outcomes Res Date: 2021-06-08